23-epi-26-Deoxyactein(Synonyms: 27-Deoxyactein)


23-epi-26-Deoxyactein (Synonyms: 27-Deoxyactein)

23-epi-26-Deoxyactein 是天然的、具有口服活性的抗肥胖和抗肿瘤作用的化合物。

23-epi-26-Deoxyactein(Synonyms: 27-Deoxyactein)

23-epi-26-Deoxyactein Chemical Structure

CAS No. : 501938-01-8

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.


23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound[1][2][3].

(In Vitro)

23-epi-26-Deoxyactein (DA :10 μM and 20 μM) inhibits 3T3-L1 adipogenesis through down-regulating the expression of C/ebpα, C/ebpβ, and Pparγ, which are the critical adipogenic transcription factors[1].
23-epi-26-Deoxyactein (DA) promotes mitochondrial biogenesis in pancreatic β-cells preventing methylglyoxal-induced oxidative cell damage and protects osteoblasts against Antimycin A-induced cell damage[2].
23-epi-26-Deoxyactein (DA) inhibits growth of the MCF7 human breast cancer cells and induces cell cycle arrest at G1 (IC50 of 21μM)[3].
23-epi-26-Deoxyactein (0.1-1 μM) protects osteoblasts against Antimycin A-induced cell damage[4].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay[1]

Cell Line: 3T3-L1 preadipocytes.
Concentration: 0-50 μM.
Incubation Time: 8 days.
Result: 10 μM DA inhibited the adipogenesis of 3T3-L1 preadipocytes mainly at the early stage of differentiation.

(In Vivo)

23-epi-26-Deoxyactein (DA: 5 and 10 mg/kg/d) significantly lowers body weight gain, fat mass, and liver weight in HFD-fed mice. 23-epi-26-Deoxyactein (DA) also reduces insulin resistance and serum lipoprotein levels in HFD-fed mice[1].
23-epi-26-Deoxyactein (DA) promotes adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Diet induced obesity in C57BL/6 mice[1].
Dosage: 1-10 mg/kg.
Administration: Orally, daily for 12 weeks.
Result: Lowered body weight gain, fat mass, and liver weight.
5 mg/kg/d DA significantly improved HFD-induced glucose intolerance.








Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • [1]. Jingjing Yuan, et al. Effects of 23-epi-26-deoxyactein on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice. Phytomedicine. 2020 Jun 5;76:153264.

    [2]. Kwang Sik Suh, et al. Deoxyactein protects pancreatic β-cells against methylglyoxal-induced oxidative cell damage by the upregulation of mitochondrial biogenesis. Int J Mol Med. 2017 Aug;40(2):539-548.

    [3]. Einbond, L.S., et al. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. Breast Cancer Res. Treat. 83, 221–231. Breast Cancer Res Treat. 2004 Feb;83(3):221-31.

    [4]. Eun Mi Choi, et al. Deoxyactein Isolated from Cimicifuga racemosa protects osteoblastic MC3T3-E1 cells against antimycin A-induced cytotoxicity. J Appl Toxicol. 2013 Jun;33(6):488-94.